Related Experiment Video
Updated: May 11, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic
Rebecca Voltan1, Paola Secchiero, Barbara Ruozi
1Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.
Purpose:
Because the nongenotoxic inhibitor of the p53/MDM2 interactions Nutlin-3 has shown promising in vitro therapeutic activity against a variety of p53(wild-type) cancer cells, in this study we evaluated an innovative strategy able to specifically target Nutlin-3 toward CD20(+) malignant cells.
Experimental Design:
The cytotoxic effects of Nutlin-3 encapsulated into poly(lactide-co-glycolide) nanoparticles (NP-Nut) and into rituximab (anti-CD20 antibody)-engineered NP (NP-Rt-Nut) as well as of NPs engineered with rituximab alone (NP-Rt) were initially analyzed in vitro in JVM-2 B-leukemic cells, by assessing both the functional activation of the p53 pathway (by Nutlin-3) and/or the activation of the complement cascade (by rituximab). Moreover, the potential therapeutic efficacy of NP-Nut, NP-Rt, and NP-Rt-Nut were comparatively assessed in vivo in CD20(+) JVM-2 leukemic xenograft SCID mice.
Results:
Functional in vitro assays showed that NP-Nut and NP-Rt-Nut exhibited a comparable ability to activate the p53 pathway in the p53(wild-type) JVM-2 leukemic cells. On the other hand, NP-Rt and NP-Rt-Nut, but not NP nor NP-Nut, were able to promote activation of the complement cascade. Of note, the in vivo intratumoral injection in JVM-2 B-leukemic/xenograft mice showed that NP-Rt-Nut displayed the maximal therapeutic activity promoting a survival rate significantly higher not only with respect to control animals, treated either with vehicle or with empty NP, but also with respect to animals treated with NP-Nut or NP-Rt.
Conclusions:
Our data show for the first time the potential antileukemic activity of rituximab-engineered Nutlin-3-loaded NPs in xenograft SCID mice.
Insights
This study developed targeted nanoparticles carrying Nutlin-3, a p53/MDM2 inhibitor, for CD20(+) leukemia. Rituximab-engineered nanoparticles showed superior therapeutic efficacy in preclinical models, highlighting their antileukemic potential.
Area of Science:
- Oncology
- Nanomedicine
- Immunotherapy
Background:
- Nutlin-3, a p53/MDM2 interaction inhibitor, demonstrates in vitro efficacy against wild-type p53 cancers.
- Targeting strategies are crucial for enhancing therapeutic delivery to specific cancer cells.
Purpose of the Study:
- To evaluate a novel strategy for targeted delivery of Nutlin-3 to CD20-expressing malignant cells.
- To assess the therapeutic potential of rituximab-engineered nanoparticles loaded with Nutlin-3.
Main Methods:
- Nutlin-3 was encapsulated into poly(lactide-co-glycolide) nanoparticles (NP-Nut).
- Nanoparticles were engineered with rituximab (anti-CD20 antibody) for targeted delivery (NP-Rt-Nut).
- In vitro and in vivo studies were conducted using JVM-2 B-leukemic cells and xenograft models in SCID mice.
Main Results:
- NP-Nut and NP-Rt-Nut effectively activated the p53 pathway in vitro.
- Rituximab-containing nanoparticles (NP-Rt and NP-Rt-Nut) activated the complement cascade.
- Intratumoral administration of NP-Rt-Nut significantly improved survival rates in vivo compared to controls and other nanoparticle formulations.
Conclusions:
- Rituximab-engineered Nutlin-3-loaded nanoparticles demonstrate significant antileukemic activity.
- This targeted nanoparticle approach shows promise for treating CD20(+) leukemias.
More Related Videos
08:09Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
09:02Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024